However, resistance formation after an initial therapy response is common, and new therapies are needed for NSCLC patients, whose tumours have stopped responding to EGFR tyrosine kinase inhibitor therapy [1, 2, 3, 4, 5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.